{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:19:56Z","timestamp":1784762396916,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":656,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Hispania SL"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril\u2013valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the cyclic guanosine monophosphate deficiency has a negative direct impact on the pathogenesis of HF, and vericiguat, an oral stimulator of soluble guanylate cyclase, can restore this pathway. The effect of vericiguat has been explored in the VICTORIA study, the largest chronic HF clinical trial that has mainly focused on patients with recent worsening HF, evidencing a significant 10% risk reduction of the primary composite endpoint of cardiovascular death or HF hospitalization (number needed to treat 24), after adding vericiguat to standard therapy. This benefit was independent of background HF therapy. Therefore, optimization of treatment should be performed as earlier as possible, particularly within vulnerable periods, considering also the use of vericiguat.<\/jats:p>","DOI":"10.1002\/ehf2.14647","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:34:18Z","timestamp":1703896458000},"page":"628-636","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of Vericiguat in Management of Patients with Heart Failure with Reduced Ejection Fraction After Worsening Episode"],"prefix":"10.1093","volume":"11","author":[{"given":"Aleix","family":"Olivella","sequence":"first","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Hospital Universitari Vall d'Hebr\u00f3n, Vall d'Hebr\u00f3n Institut de Recerca (VHIR), Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almenar-Bonet","sequence":"additional","affiliation":[{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Heart Failure and Transplantation Unit, Department of Cardiology, Hospital Universitari i Polit\u00e8cnic La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moliner","sequence":"additional","affiliation":[{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Community Heart Failure Program (UMICO), Department of Cardiology, Bellvitge University Hospital , Barcelona ,","place":["Spain"]},{"name":"Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Coloma","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Internal Medicine Department and Hospital at Home Unit, Hospital Clinic , Barcelona ,","place":["Spain"]},{"name":"Instituto de Investigaciones M\u00e9dicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Mart\u00ednez-Rubio","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Sabadell , Sabadell ,","place":["Spain"]},{"name":"Universidad Autonoma de Barcelona , Sabadell ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paz Bermejo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Santa Caterina , Girona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Boixeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital de Matar\u00f3 , Matar\u00f3 ,","place":["Spain"]},{"name":"Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Cediel","sequence":"additional","affiliation":[{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Heart Failure Unit, Department of Cardiology, Hospital Universitari Germans Trias I Pujol , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"M\u00e9ndez Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Hospital Universitari Vall d'Hebr\u00f3n, Vall d'Hebr\u00f3n Institut de Recerca (VHIR), Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1402-4364","authenticated-orcid":false,"given":"Lorenzo","family":"Facila Rubio","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital General de Valencia, Universitat de Valencia , Avda. Tres Cruces 2, 46014, Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"2026012113160299100_ehf214647-bib-0001","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: A report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2026012113160299100_ehf214647-bib-0002","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure. A contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"2026012113160299100_ehf214647-bib-0003","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026012113160299100_ehf214647-bib-0004","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/jcm11175199","article-title":"Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"11","author":"Escobar","year":"2022","journal-title":"J Clin Med"},{"key":"2026012113160299100_ehf214647-bib-0005","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1186\/s12913-022-08614-x","article-title":"Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"22","author":"Escobar","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2026012113160299100_ehf214647-bib-0006","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ejhf.549","article-title":"Medical resource use and expenditure in patients with chronic heart failure: A population-based analysis of 88 195 patients","volume":"18","author":"Farr\u00e9","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0007","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113160299100_ehf214647-bib-0008","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ejhf.2382","article-title":"In-hospital initiation of quadruple medical therapy for heart failure: Making the post-discharge vulnerable phase far less vulnerable","volume":"24","author":"Greene","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0009","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026012113160299100_ehf214647-bib-0010","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"2026012113160299100_ehf214647-bib-0011","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0012","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/ejhf.2720","article-title":"Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0013","doi-asserted-by":"publisher","first-page":"54","DOI":"10.12968\/pnur.2021.32.2.54","article-title":"Understanding the pathogenesis of heart failure","volume":"32","author":"Easa","year":"2021","journal-title":"Pract Nurs"},{"key":"2026012113160299100_ehf214647-bib-0014","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026012113160299100_ehf214647-bib-0015","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012113160299100_ehf214647-bib-0016","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J Cardiol"},{"key":"2026012113160299100_ehf214647-bib-0017","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0018","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"2026012113160299100_ehf214647-bib-0019","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026012113160299100_ehf214647-bib-0020","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"2026012113160299100_ehf214647-bib-0021","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0022","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026012113160299100_ehf214647-bib-0023","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026012113160299100_ehf214647-bib-0024","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10741-019-09881-3","article-title":"Role of endothelial dysfunction in heart failure","volume":"25","author":"Zuchi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026012113160299100_ehf214647-bib-0025","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/HYPERTENSIONAHA.117.10406","article-title":"Angiotensin-(1\u20137) and vascular function: The clinical context","volume":"71","author":"Touyz","year":"2018","journal-title":"Hypertension"},{"key":"2026012113160299100_ehf214647-bib-0026","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0027","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM198711193172112","article-title":"Enalapril for congestive heart failure","volume":"317","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0028","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2026012113160299100_ehf214647-bib-0029","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026012113160299100_ehf214647-bib-0030","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0031","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0032","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0033","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: A review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"2026012113160299100_ehf214647-bib-0034","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0035","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14740\/cr1221","article-title":"A review of the proposed mechanistic actions of sodium glucose cotransporter-2 inhibitors in the treatment of heart failure","volume":"12","author":"Nightingale","year":"2021","journal-title":"Cardiol Res"},{"key":"2026012113160299100_ehf214647-bib-0036","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/diagnostics12040989","article-title":"Sodium-glucose cotransporter-2 inhibitors improve heart failure with reduced ejection fraction outcomes by reducing edema and congestion","volume":"12","author":"Hernandez","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026012113160299100_ehf214647-bib-0037","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0038","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012113160299100_ehf214647-bib-0039","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10741-021-10146-1","article-title":"The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction","volume":"27","author":"Aimo","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026012113160299100_ehf214647-bib-0040","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/biomedicines10102471","article-title":"Vericiguat in heart failure: Characteristics, scientific evidence and potential clinical applications","volume":"10","author":"Vannuccini","year":"2022","journal-title":"Biomedicine"},{"key":"2026012113160299100_ehf214647-bib-0041","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"2026012113160299100_ehf214647-bib-0042","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0043","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Cinaciguat, a soluble guanylate cyclase activator: Results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0044","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012113160299100_ehf214647-bib-0045","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0046","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1080\/14656566.2022.2116275","article-title":"Individualizing the treatment of patients with heart failure with reduced ejection fraction: A journey from hospitalization to long-term outpatient care","volume":"23","author":"Escobar","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2026012113160299100_ehf214647-bib-0047","volume-title":"Summary of product characteristics","author":"Vericiguat","year":"2021"},{"key":"2026012113160299100_ehf214647-bib-0048","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113160299100_ehf214647-bib-0049","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.08","article-title":"In-hospital initiation and up-titration of guideline-directed medical therapies for heart failure with reduced ejection fraction","volume":"8","author":"Cox","year":"2022","journal-title":"Card Fail Rev"},{"key":"2026012113160299100_ehf214647-bib-0050","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","author":"Writing Committee Members","year":"2022","journal-title":"J Card Fail"},{"key":"2026012113160299100_ehf214647-bib-0051","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.rec.2021.11.023","article-title":"Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"75","author":"SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026012113160299100_ehf214647-bib-0052","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026012113160299100_ehf214647-bib-0053","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0054","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113160299100_ehf214647-bib-0055","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: Insights from the VICTORIA trial","volume":"24","author":"Senni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0056","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to vericiguat according to index heart failure event: Insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113160299100_ehf214647-bib-0057","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: Insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113160299100_ehf214647-bib-0058","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/ehf2.14050","article-title":"Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: Analyses from the VICTORIA trial","volume":"9","author":"Senni","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/628\/64540165\/eschf_11_2_628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/628\/64540165\/eschf_11_2_628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:18:03Z","timestamp":1769019483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/2\/628\/8271359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,29]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14647","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"2023-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}